Bioinformatics & omics

Computation and storage carried out in molecules and living tissue rather than silicon — DNA archives with in-sequencer random access, error-correction codecs tolerating error rates near 14% and sequence loss up to 65%, genetic circuits implementing half and full adders, and biohybrid systems that compute with slime mould and fungal networks.

Sequencing, single-cell and spatial omics, and biological AI that turn raw reads into decisions — a stack from sample to interpreted multi-omics.

The AI, machine-learning and bioinformatics software-as-a-service layer — cloud platforms, generative biological foundation models and managed analysis pipelines — sold to pharma, biotech and industrial-biology teams rather than run as in-house drug pipelines.

Writing genomes rather than just reading them — DNA synthesis at scale, de novo synthetic chromosomes and DNA-based digital data storage, complementing the sequencing/analysis side of genomics.

Third-generation (long-read) sequencing as a service — PacBio HiFi and Oxford Nanopore platforms resolving repeats, structural variants and direct epigenetic modifications that short-read NGS cannot.

Contract research platforms that profile the small-molecule metabolome of blood, tissue or bioreactor broth via LC-MS/GC-MS, turning raw chromatography data into biomarker panels, drug-response readouts and bioprocess metabolic profiles for pharma, nutrition and industrial-fermentation clients.

Mass-spectrometry proteomics as a contract research service — deep DIA proteome profiling, targeted MRM/PRM and affinity proteomics for biomarker discovery and pharmacoproteomics.

Per-cell mapping of genomes, transcriptomes and proteomes as a contracted service — moving biology from bulk-average reads to cell-by-cell atlases for drug-target discovery and patient stratification.

Mapping chromatin accessibility, DNA methylation and histone marks directly on a tissue section instead of a dissociated cell suspension, using in situ Tn5 transposition and microfluidic barcoding to build 3D atlases of a tumor's epigenetic state at 10-micron resolution — the layer of hardware and reagents beneath precision oncology's biggest 2026 push.

Mapping gene expression — and increasingly proteins — directly onto intact tissue sections, so each transcript keeps its x/y address and the tumour microenvironment becomes a navigable map rather than a bulk average.

Cryo-electron microscopy as a contract research service — atomic 3D structures of membrane proteins and drug targets for structure-based drug design, displacing X-ray crystallography.

Contract safety assessment that takes a drug candidate from in-silico ADMET triage through in-vitro panels (hepatotoxicity, hERG, CYP induction) to GLP in-vivo studies, delivering the IND-enabling toxicity package regulators require — now augmented by toxicogenomics and virtual control groups.